Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $914K fell 50.9% year over year, in line with the -50.6% change in trailing-twelve-month other income / expenses. Sequentially, it fell 21.2% from the prior quarter. Over 3 fiscal years it compounded at +65.3% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -50.9% toward the trailing-twelve-month pace of -50.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 6.75M USD
- Year-over-year change
- -23.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.75M | -23.3% |
| FY2024 | 2024-12-31 | 8.79M | +188.4% |
| FY2023 | 2023-12-31 | 3.05M | +103.9% |
| FY2022 | 2022-12-31 | 1.49M | +108.1% |
| FY2021 | 2021-12-31 | (18.55M) | — |
Other Income / Expenses vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -50.6% is the 3rd highest of 9, against a peer median of -84.5%.
- Over three fiscal years its annual growth of +65.3% compares with a peer median of +10.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.47M USD | +277.4% | — | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $5M USD | -50.6% | +65.3% | — |
| FY2025 | $2.79M USD | -60.4% | +22.4% | 4360.9% | |
| LTM Mar 2026 | $2.79M USD | -35.2% | +24.9% | 279.0% | |
| LTM Mar 2026 | $2.3M USD | -64.6% | -16.7% | — | |
| LTM Mar 2026 | -€440.14K EUR | -104.4% | -1.4% | 1500.6% | |
| LTM Mar 2026 | -$5.37M USD | -124.3% | — | 11.9% | |
| LTM Mar 2026 | -$15.12M USD | -297.9% | — | — | |
| LTM Mar 2026 | -$38.64M USD | -613.7% | — | 38.8% | |
| Peer median (excluding ARTV) | — | -84.5% | +10.5% | 279.0% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2M | 4.93M | 33.49M | 251K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.6M |
| Gross Profit | 2M | 4.93M | 33.49M | 251K | (2.6M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 42.41M | 43.98M | 50.25M | 50.33M | 69.54M |
| Selling, General & Admin | 12.86M | 20.78M | 13.91M | 17.21M | 20.27M |
| Operating Expenses | 55.27M | 64.76M | 64.16M | 67.53M | 88.01M |
| Depreciation & Amortization | 248K | 1.16M | 2.27M | 2.43M | 2.6M |
| EBITDA | (71.58M) | (57.18M) | (25.36M) | (56.06M) | (81.27M) |
| EBITDA Margin | -3575.3% | -1159.5% | -75.7% | -22335.5% | — |
| Operating Income | (53.27M) | (59.83M) | (30.67M) | (67.28M) | (90.61M) |
| Operating Margin | -2660.9% | -1213.3% | -91.6% | -26805.6% | — |
| Interest Income | 0 | 1.29M | 2.54M | 5.35M | 5.96M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (18.55M) | 1.49M | 3.05M | 8.79M | 6.75M |
| Income Before Tax | (71.83M) | (58.34M) | (27.62M) | (58.49M) | (83.87M) |
| Pre-Tax Margin | -3587.7% | -1183.0% | -82.5% | -23304.0% | — |
| Income Tax Expense | 0 | 53K | 72K | 0 | 0 |
| Net Income | (71.83M) | (58.39M) | (27.7M) | (58.49M) | (83.87M) |
| Net Margin | -3587.7% | -1184.1% | -82.7% | -23304.0% | — |
| EPS (Basic) | (4.08) | (3.32) | (1.19) | (5.20) | (3.43) |
| EPS (Diluted) | (4.08) | (3.32) | (1.19) | (5.20) | (3.43) |
| Weighted Avg Shares | 17.58M | 17.58M | 23.28M | 24.36M | 24.44M |
| Weighted Avg Shares (Diluted) | 17.58M | 17.58M | 23.28M | 24.36M | 24.44M |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.